Biomarkers in Renal Diseases Ⅱ

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Biomarkers".

Deadline for manuscript submissions: 31 July 2024 | Viewed by 3015

Special Issue Editors


E-Mail Website
Guest Editor
Depto. Fisiología, Universidad de Jaén, Jaén, Spain
Interests: Kidney Health and Disease; aminopeptidases; biomarkers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Medicine, Faculty of Medicine, University of Granada, 18071 Granada, Spain
Interests: health and disease; uremic toxins; transplantation; biomarkers
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Nephrology Unit, Universitary Hospital Virgen de las Nieves, 18014 Granada, Spain
Interests: Kidney Health and Disease; chronic kidney disease; transplantation; biomarkers
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following a very successful first issue, we are pleased to announce the launch of a second edition of Biomarkers in Renal Diseases.

Early detection and monitoring of renal disease remains challenging. Traditional markers such as serum creatinine and proteinuria begin to increase when renal function is already diminished or renal lesions are evident. Therefore, the sensitivity and specificity of these markers may be insufficient for the diagnosis and prognosis of several renal pathologies.

For this Special Issue, we are seeking experimental and clinical articles or reviews concerning biomarkers of acute kidney injury or chronic kidney disease that can increase the sensitivity and specificity of traditional markers, contributing to the early diagnosis of renal diseases and helping to determine a prognosis. Articles may include biomarkers that are present in any biological sample, such as blood, urine, or even extracellular vesicles isolated from urine.

Prof. Dr. Rosemary Wangensteen
Dr. Antonio Osuna Ortega
Dr. María del Carmen de Gracia Guindo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • biomarkers
  • acute kidney injury
  • chronic kidney disease
  • microvesicles
  • exosomes

Related Special Issue

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 743 KiB  
Review
Toward Precision Medicine: Exploring the Landscape of Biomarkers in Acute Kidney Injury
by Nicole Nourie, Rita Ghaleb, Carmen Lefaucheur and Kevin Louis
Biomolecules 2024, 14(1), 82; https://0-doi-org.brum.beds.ac.uk/10.3390/biom14010082 - 08 Jan 2024
Viewed by 1422
Abstract
Acute kidney injury (AKI) remains a complex challenge with diverse underlying pathological mechanisms and etiologies. Current detection methods predominantly rely on serum creatinine, which exhibits substantial limitations in specificity and poses the issue of late-stage detection of kidney injury. In this review, we [...] Read more.
Acute kidney injury (AKI) remains a complex challenge with diverse underlying pathological mechanisms and etiologies. Current detection methods predominantly rely on serum creatinine, which exhibits substantial limitations in specificity and poses the issue of late-stage detection of kidney injury. In this review, we propose an up-to-date and comprehensive summary of advancements that identified novel biomarker candidates in blood and urine and ideal criteria for AKI biomarkers such as renal injury specificity, mechanistic insight, prognostic capacity, and affordability. Recently identified biomarkers not only indicate injury location but also offer valuable insights into a range of pathological processes, encompassing reduced glomerular filtration rate, tubular function, inflammation, and adaptive response to injury. The clinical applications of AKI biomarkers are becoming extensive and serving as relevant tools in distinguishing acute tubular necrosis from other acute renal conditions. Also, these biomarkers can offer significant insights into the risk of progression to chronic kidney disease CKD and in the context of kidney transplantation. Integration of these biomarkers into clinical practice has the potential to improve early diagnosis of AKI and revolutionize the design of clinical trials, offering valuable endpoints for therapeutic interventions and enhancing patient care and outcomes. Full article
(This article belongs to the Special Issue Biomarkers in Renal Diseases Ⅱ)
Show Figures

Figure 1

16 pages, 2275 KiB  
Review
Biomarkers Associated with Drugs for the Treatment of Lupus Nephritis
by Huiyu Nie, Siyuan Chang, Yuanyuan Li and Fen Li
Biomolecules 2023, 13(11), 1601; https://0-doi-org.brum.beds.ac.uk/10.3390/biom13111601 - 31 Oct 2023
Viewed by 1283
Abstract
The constant updating of lupus drug treatment guidelines has led to a question. How can the efficacy of treatment be more effectively monitored? Systemic lupus erythematosus (SLE) is a complex autoimmune disease that often presents clinically with multi-organ involvement, and approximately 30% of [...] Read more.
The constant updating of lupus drug treatment guidelines has led to a question. How can the efficacy of treatment be more effectively monitored? Systemic lupus erythematosus (SLE) is a complex autoimmune disease that often presents clinically with multi-organ involvement, and approximately 30% of patients with SLE develop lupus nephritis (LN). Therefore, it is important to better track disease progression and drug efficacy. Now, kidney biopsy is still the gold standard for diagnosing and guiding the treatment of LN, but it is invasive and expensive. If simple, non-invasive and effective biomarkers can be found, drug intervention and prognosis can be better monitored and targeted. In this review, we focus on LN and explore biomarkers related to LN therapeutics, providing clinicians with more possibilities to track the therapeutic effect of drugs, improve treatment options and assess patient outcomes. Full article
(This article belongs to the Special Issue Biomarkers in Renal Diseases Ⅱ)
Show Figures

Figure 1

Back to TopTop